Einträge von Al Malki, Monzr M. auf dem Publikationsserver

Etra, Aaron, Capellini, Alexandra, Alousi, Amin, Al Malki, Monzr M., Choe, Hannah, DeFilipp, Zachariah, Hogan, William J., Kitko, Carrie L., Ayuk, Francis, Baez, Janna, Gandhi, Isha, Kasikis, Stelios, Gleich, Sigrun, Hexner, Elizabeth, Hoepting, Matthias, Kapoor, Urvi, Kowalyk, Steven, Kwon, Deukwoo, Langston, Amelia, Mielcarek, Marco, Morales, George, Özbek, Umut, Qayed, Muna, Reshef, Ran, Rösler, Wolf, Spyrou, Nikolaos, Young, Rachel, Chen, Yi-Bin, Ferrara, James L. M. und Levine, John E. (2023) Effective treatment of low-risk acute GVHD with itacitinib monotherapy. Blood 141 (5), S. 481-489. Volltext nicht vorhanden.

Al Malki, Monzr M., London, Kaitlyn, Baez, Janna, Akahoshi, Yu , Hogan, William J. , Etra, Aaron, Choe, Hannah, Hexner, Elizabeth , Langston, Amelia , Abhyankar, Sunil, Ponce, Doris M., DeFilipp, Zachariah, Kitko, Carrie L., Adekola, Kehinde, Reshef, Ran, Ayuk, Francis, Capellini, Alexandra, Chanswangphuwana, Chantiya, Eder, Matthias, Eng, Gilbert, Gandhi, Isha, Grupp, Stephan, Gleich, Sigrun, Holler, Ernst, Javorniczky, Nora Rebeka, Kasikis, Stelios, Kowalyk, Steven, Morales, George, Özbek, Umut, Rösler, Wolf, Spyrou, Nikolaos, Yanik, Gregory, Young, Rachel, Chen, Yi-Bin, Nakamura, Ryotaro, Ferrara, James L. M. und Levine, John E. (2023) Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease. Blood Advances 7 (17), S. 5189-5198. Volltext nicht vorhanden.